CSL Limited stock falls after Phase 3 setback (OTCMKTS:CSLLY)
cagkansayin Australian biotech CSL Limited (OTCQX:CSLLY) fell ~4% on Monday, marking its biggest intraday loss in more than four months after its Phase 3 AEGIS-II trial, one of its key clinical programs, failed. The global trial was…
